Abstract
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have